Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities

Aducanumab is a monoclonal antibody selective for amyloid β (Aβ) aggregates. In June 2021, aducanumab became the first drug underlying the pathophysiology of Alzheimer’s disease (AD) approved by the US Food and Drug Administration (FDA), under the accelerated approval pathway. The decision was based...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaz, Miguel, Silva, Vítor, Monteiro, Cristina, Silvestre, Samuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124475/
https://www.ncbi.nlm.nih.gov/pubmed/35611326
http://dx.doi.org/10.2147/CIA.S325026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124475/
https://www.ncbi.nlm.nih.gov/pubmed/35611326
http://dx.doi.org/10.2147/CIA.S325026

Ejemplares similares